News | ASH Releases New Treatment Standards for AYA Leukemia
The American Society of Hematology (ASH) has released new clinical guidelines for treating acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), covering initial treatment and management strategies for relapsed or refractory disease. Developed by pediatric and adult hematologic oncology experts together with patient representatives, the evidence-based guidelines aim to improve outcomes in this distinct age group and have been published in the Society’s peer-reviewed journal, Blood Advances.
ASH President Robert Negrin noted that treating AYA patients is highly complex because this group is neither fully suited to traditional pediatric regimens nor easily managed with adult treatment models. “The new guidelines aim to fill this clinical gap by standardizing treatment pathways and improving overall quality of care.”
Both sets of guidelines call for more clinical research involving AYA patients with ALL, including trials directly comparing different immunotherapy regimens and studies exploring whether more patients can avoid hematopoietic stem cell transplantation without compromising efficacy.
Key Points in the Initial Treatment Guidelines
The frontline treatment guidelines include 15 recommendations and several good practice statements. Key points include:
Prioritize pediatric-inspired regimens over traditional adult regimens
Establish asparaginase as a key treatment and provide recommendations on administration and supportive care
Given insufficient evidence, do not routinely perform allogeneic transplantation during first remission; its role should be reassessed
Guideline co-chair Wendy Stock, professor of medicine at the University of Chicago, said the new guidelines address many clinical challenges in greater detail, including management of chemotherapy side effects, psychosocial support, and long-term survivorship, with particular attention to fertility preservation. “We are in a period of rapid advances in disease monitoring and treatment strategies, creating unprecedented opportunities for patients.”
Management of Relapsed/Refractory Disease
For relapsed or refractory ALL, the guidelines provide eight treatment recommendations and one research recommendation. Key points include:
Prioritize immunotherapy over conventional chemotherapy
Consider allogeneic transplantation for patients who achieve remission, with individualized assessment and shared clinician-patient decision-making to weigh risks and benefits
Recommend intrathecal chemotherapy for isolated central nervous system relapse
Guideline co-chair Sumit Gupta, professor of pediatrics at the University of Toronto, also leads the Leukemia/Lymphoma Section at the Hospital for Sick Children. He noted that the field faces two major challenges: the rapid pace of technological change and the need to bridge pediatric and adult oncology care systems. “We hope these guidelines encourage more interdisciplinary collaboration and truly improve patient outcomes.”
ALL in the AYA Population
Acute lymphoblastic leukemia is a rapidly progressing malignancy of the blood and bone marrow caused by excessive proliferation of abnormal immature white blood cells. These cells cannot effectively fight infection and interfere with red blood cell and platelet production.
About 20% of ALL cases occur among AYAs aged 15 to 39. Historically, patients in this age group have had lower long-term survival rates and a higher risk of relapse than children. This disparity is partly due to a higher prevalence of high-risk biological features, greater treatment toxicity, and inconsistent treatment pathways.
ASH stated that the complete guideline resources also include visual abstracts, infographics, and educational materials for clinicians.
News | ASH Issues New Standard for Treating AYA Leukemia
News | ASH Releases New Treatment Standards for AYA Leukemia
The American Society of Hematology (ASH) has released new clinical guidelines for treating acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), covering initial treatment and management strategies for relapsed or refractory disease. Developed by pediatric and adult hematologic oncology experts together with patient representatives, the evidence-based guidelines aim to improve outcomes in this distinct age group and have been published in the Society’s peer-reviewed journal, Blood Advances.
ASH President Robert Negrin noted that treating AYA patients is highly complex because this group is neither fully suited to traditional pediatric regimens nor easily managed with adult treatment models. “The new guidelines aim to fill this clinical gap by standardizing treatment pathways and improving overall quality of care.”
Both sets of guidelines call for more clinical research involving AYA patients with ALL, including trials directly comparing different immunotherapy regimens and studies exploring whether more patients can avoid hematopoietic stem cell transplantation without compromising efficacy.
Key Points in the Initial Treatment Guidelines
The frontline treatment guidelines include 15 recommendations and several good practice statements. Key points include:
Prioritize pediatric-inspired regimens over traditional adult regimens
Establish asparaginase as a key treatment and provide recommendations on administration and supportive care
Given insufficient evidence, do not routinely perform allogeneic transplantation during first remission; its role should be reassessed
Guideline co-chair Wendy Stock, professor of medicine at the University of Chicago, said the new guidelines address many clinical challenges in greater detail, including management of chemotherapy side effects, psychosocial support, and long-term survivorship, with particular attention to fertility preservation. “We are in a period of rapid advances in disease monitoring and treatment strategies, creating unprecedented opportunities for patients.”
Management of Relapsed/Refractory Disease
For relapsed or refractory ALL, the guidelines provide eight treatment recommendations and one research recommendation. Key points include:
Prioritize immunotherapy over conventional chemotherapy
Consider allogeneic transplantation for patients who achieve remission, with individualized assessment and shared clinician-patient decision-making to weigh risks and benefits
Recommend intrathecal chemotherapy for isolated central nervous system relapse
Guideline co-chair Sumit Gupta, professor of pediatrics at the University of Toronto, also leads the Leukemia/Lymphoma Section at the Hospital for Sick Children. He noted that the field faces two major challenges: the rapid pace of technological change and the need to bridge pediatric and adult oncology care systems. “We hope these guidelines encourage more interdisciplinary collaboration and truly improve patient outcomes.”
ALL in the AYA Population
Acute lymphoblastic leukemia is a rapidly progressing malignancy of the blood and bone marrow caused by excessive proliferation of abnormal immature white blood cells. These cells cannot effectively fight infection and interfere with red blood cell and platelet production.
About 20% of ALL cases occur among AYAs aged 15 to 39. Historically, patients in this age group have had lower long-term survival rates and a higher risk of relapse than children. This disparity is partly due to a higher prevalence of high-risk biological features, greater treatment toxicity, and inconsistent treatment pathways.
ASH stated that the complete guideline resources also include visual abstracts, infographics, and educational materials for clinicians.
Story source:
Collected online